Filgrastim
Ford Motor Co. has recalled 262, 113 Ford Escape sport utility vehicles to repair a defect in the rear gate. The recall, the second for the vehicles during December, covers 2001-2005 models whose rear lift gate could open during a crash. The National Highway Traffic Safety Administration reported the recall on its website. In addition.
Two MTW consumption, as computed by the JCHEMRATES IV study March 1999 data ; . Those quantities represented the minimum requirements for full sustainment through two conflicts. Recognizing that potentially U.S. forces would be left depleted of resources after the conflicts, the Logistics Support Plan Integrated Product Team IPT ; added initial issue quantities to consumption in calculating the two MTW requirement for consumable items. The consumption that is used to compute the two MTW requirement provided in Tables F-1 through F-5 is based on the final JCHEMRATES IV calculations dated March 1999. The Services and the JNBCDB have the option of providing different requirements if they determine the JCHEMRATES calculations to be inaccurate or outdated. Note that materiel requirements for training, sizing variations and peacetime replacements are not included in the wartime requirements calculated by JCHEMRATES. This number represents an average expenditure calculated among four scenarios: chemical defense equipment expenditures under low chemical weapons use during favorable and marginal weather conditions; and of chemical defense equipment expenditures against high chemical weapons use during favorable and marginal weather conditions. All sets of conditions were run for the North-East Asia and South-West Asia scenarios. The "STOCKS ON-HAND" represents the total of all serviceable NBC defense materiel available in each of the Services stocks positioned with troops, stocks in the supply system and stocks stored in depots facilities, both peacetime stores and war reserve ; . This number represents only those items physically "on-hand". Quantities for which a Service or agency has submitted a funded requisition or purchase order in FY01, but has not received the requisitioned items are included in FY02. Finally, the quantities depicted as "PROJECTED DUE-IN" are quantities the Services plan to buy to replace peacetime consumption of NBC defense assets to include training use and shelf-life expiration ; , and to buy wartime sustainment stocks. It must be emphasized that these numbers are based on major command estimates of requirements. Actual procurements are contained within the On-Hand Column!
Premature Take with food 1.5 mg kg q 12hr Hematoxicity: Interrupt therapy or decrease dose or Neo use erythropoietin, 2 mg kg po q6hr filgrastim 1.5 mg kg IV q6hr IV: Infuse over 1 hour; Pediatrics dilute with D5W to 4 60-180 mg m2 po q6-8hr mg ml; refrigerated stable usual 160 mg m2 po q8hr ; for 24 hours IV intermittent: 60-120 2 q6hr mg m IV continuous: 20 mg m2 hr Adolescent Adult 200 mg tid or 300 mg bid Pediatrics 8 mg kg twice daily Adolescent Adult 16 yrs: 300 mg bid Store at room temperature Required: warning card and patient package insert.
Filgrastim appears to have a significant role in increasing peripheral anc and enhancing neutrophil function in patients with hiv infection and aids.
Drugs x oncovin vincristine x paraplatin carboplatin x photofrin porfimer sodium x platinol cisplatin x prednisone prednisone x purinethol mercaptopurine x quadramet samarium 153 lexidronan x taxol paclitaxel x taxotere docetaxel x x temodal temozolomide x thalomid thalidomide x thioguanine 6-thioguanine x thioplex thiotepa x trisenox arsenic trioxide x valstar valrubicin x velban vinblastine x velcade bortezomib x vepesid etoposide x vesanoid tretinoin x vumon teniposide x xeloda capecitabine x zanosar streptozocin x zevalin ibritumomab tiuxetan x biologic agents aranesp darbepoetin alfa x herceptin trastuzumab x introna interferon x leukine sargramostim x neulasta pegfilgrastim x neumega oprelvekin x neupogen filgrastim x procrit epoetin alfa x proleukin aldesleukin x rituxan rituximab x references eisenberg p, figueroa-vadillo j, zamora r, et al improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-ht3 receptor antagonist: results of a phase iii, single-dose trial versus dolasetron.
1. Sekeres M, Dodge R, Bloomfield C, Larson R, Stone R. Racial differences in prognostic factors and outcome in acute myeloid leukemia AML ; : a Cancer and Leukemia Group B CALGB ; study [abstract]. Blood. 2002; 100: 323a. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999; 341: 10511062. Ries L, Eisner M, Kosary C, eds. SEER Cancer Statistics Review, 1973-1999. Bethesda, MD: National Cancer Institute; 2002. Available at: : seer ncer.gov csr 1973 1999 . Accessed February 24, 2004. 4. Beart RW, Steele GD Jr, Menck HR, Chmiel JS, Ocwieja KE, Winchester DP. Management and survival of patients with adenocarcinoma of the colon and rectum: a national survey of the Commission on Cancer. J Coll Surg. 1995; 181: 225-236. Bradley CJ, Given CW, Roberts C. Disparities in cancer diagnosis and survival. Cancer. 2001; 91: 178-188. Marbella AM, Layde PM. Racial trends in agespecific breast cancer mortality rates in US women. J Public Health. 2001; 91: 118-121. Hoffman RM, Gilliland FD, Eley JW, et al. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2001; 93: 388-395. Marcella S, Miller JE. Racial differences in colorectal cancer mortality: the importance of stage and socioeconomic status. J Clin Epidemiol. 2001; 54: 359-366. Miller B, Kolonel L, Bernstein L, et al. Racial ethnic patterns of cancer in the United States 19881992. Bethesda, MD: National Cancer Institute; 1996: 64-67. NIH Publication Number 96-4104. 10. Newman LA, Kuerer HM, Hunt KK, et al. Response to induction chemotherapy in black and white patients with locally advanced breast cancer. Breast J. 2000; 6: 242-246. Roetzheim RG, Gonzalez EC, Ferrante JM, Pal N, Van Durme DJ, Krischer JP. Effects of health insurance and race on breast carcinoma treatments and outcomes. Cancer. 2000; 89: 22022213. Pinkel D. Ethnicity and survival in children with acute lymphoid leukemia. Leukemia. 1993; 7 suppl 2 ; : S146-S147. 13. Pui CH, Boyett JM, Hancock ML, Pratt CB, Meyer WH, Crist WM. Outcome of treatment for childhood cancer in black as compared with white children: the St Jude Children's Research Hospital experience, 1962 through 1992. JAMA. 1995; 273: 633-637. Bhatia S, Sather HN, Heerema NA, Trigg ME, Gaynon PS, Robison LL. Racial and ethnic differences in survival of children with acute lymphoblastic leukemia. Blood. 2002; 100: 1957-1964. Douer D, Preston-Martin S, Chang E, Nichols PW, Watkins KJ, Levine AM. High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood. 1996; 87: 308-313. Ruiz-Arguelles GJ. Promyelocytic leukemia in Mexican Mestizos. Blood. 1997; 89: 348-349. Estey E, Thall P, Kantarjian H, Pierce S, Kornblau S, Keating M. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia. 1997; 11: 1661-1664. Howe H, Wingo P, Thun M, et al. Annual report to the nation on the status of cancer 1973 through 1998 ; , featuring cancers with recent increasing trends. J Natl Cancer Inst. 2001; 93: 824-842. Robbins AS, Whittemore AS, Van Den Eeden SK. Race, prostate cancer survival, and membership in a large health maintenance organization. J Natl Cancer Inst. 1998; 90: 986-990. Roach M III, Cirrincione C, Budman D, et al. Race and survival from breast cancer: based on Cancer and Leukemia Group B trial 8541. Cancer J Sci Am. 1997; 3: 107-112. Kalwinsky DK, Rivera G, Dahl GV, et al. Variation by race in presenting clinical and biologic features of childhood acute lymphoblastic leukaemia: implications for treatment outcome. Leuk Res. 1985; 9: 817-823. Easaw SJ, Lake DE, Beer M, Seiter K, Feldman EJ, Ahmed T. Graft-versus-host disease: possible higher risk for African American patients. Cancer. 1996; 78: 1492-1497. Chen CL, Liu Q, Pui CH, et al. Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. Blood. 1997; 89: 1701-1707. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994; 331: 896-903. Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med. 1995; 332: 1671-1677. Moore JO, Dodge RK, Amrein PC, et al. Granulocyte-colony stimulating factor filgrastim ; accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022. Blood. 1997; 89: 780-788. Moore J, Powell B, Velez-Garcia E, et al. A comparison of sequential non-cross resistant therapy or ARA-C consolidation following complete remission in adult patients less than 60 years with acute myeloid leukemia: CALGB 9222 [abstract]. Proc Soc Clin Oncol. 1997; 16: 14a. Lee E, George S, Caligiuri M, et al. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of Cancer and Leukemia Group B study 9420. J Clin Oncol. 1999; 17: 28312839. Kolitz J, George S, Dodge R, et al. Consolidation therapy by cytogenetic risk in adults with acute myeloid leukemia AML ; 60 years in first complete remission CR ; : results of CALGB 9621 [abstract]. Blood. 2001; 98: 688a. Farag SS, George SL, Lee EJ, et al. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B Study 9420. Clin Cancer Res. 2002; 8: 2812-2819. Baer MR, George SL, Dodge RK, et al. Phase 3 study of the multidrug resistance modulator PSC833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood. 2002; 100: 1224-1232. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990; 8: 813-819. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse and overall survival in adult patients with de novo acute myeloid leukemia: results from CALGB 8461. Blood. 2002; 100: 4325-4336. Baer MR, Stewart CC, Dodge RK, et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection Cancer and Leukemia Group B Study 8361 ; . Blood. 2001; 97: 35743580. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Stat Assoc. 1958; 43: 457-481. Stone RM, Berg DT, George SL, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood. 2001; 98: 548-553. US Bureau of the Census. Census 2000 Redistricting Data P.L. 94-171 ; Summary File for States. Washington, DC: US Bureau of the Census; 2001: Tables PL1, PL2, PL3, and PL4. 38. Perlin SA, Wong D, Sexton K. Residential proximity to industrial sources of air pollution: interrelationships among race, poverty, and age. J Air Waste Manag Assoc. 2001; 51: 406-421. Wing S, Richardson D, Wolf S, Mihlan G, Crawford-Brown D, Wood J. A case control study of multiple myeloma at four nuclear facilities. Ann Epidemiol. 2000; 10: 144-153. Crist WM, Carroll AJ, Shuster JJ, et al. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t 1; 19 ; q23; p13 ; : a Pediatric Oncology Group study. Blood. 1990; 76: 117-122. Laver JH, Hulsey TC, Jones JP, Gautreaux M, Barredo JC, Abboud MR. Assessment of barriers to bone marrow donation by unrelated African American potential donors. Biol Blood Marrow Transplant. 2001; 7: 45-48. Perkins HA, Hansen JA. The U.S. National Marrow Donor Program. J Pediatr Hematol Oncol. 1994; 16: 30-34. Dignam JJ, Colangelo L, Tian W, et al. Outcomes among African Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst. 1999; 91: 1933-1940. Hodgson DC, Fuchs CS, Ayanian JZ. Impact of patient and provider characteristics on the treatment and outcomes of colorectal cancer. J Natl Cancer Inst. 2001; 93: 501-515. Cella DF, Orav EJ, Kornblith AB, et al. Socioeconomic status and cancer survival. J Clin Oncol. 1991; 9: 1500-1509 and flax.
The introduction of highly active antiretroviral therapy HAART ; had a dramatic impact on the morbidity and mortality of human immunodeficiency virus HIV ; -infected patients with a decline in the incidence of several opportunistic infections, as well as of acquired immunodeficiency syndrome AIDS ; -defining malignancies [1]. On the other hand, due to the prolonged life expectancy and the ageing of the HIV-positive population, tumours are now the major cause of death [2] and among them colorectal cancers constitute a significant fraction of all cancers. Oxaliplatin is an antineoplastic agent currently indicated for use with fluorouracil and leucovorin for the treatment of advanced colorectal cancer CRC ; [3]. The feasibility and efficacy of concomitant oxaliplatin and HAART is still unknown in patients with HIV infection and metastatic CRC. Up to now, there are no published data on treatment patterns, response to therapy, or survival in this patient population. Five consecutive patients with HIV infection and metastatic CRC were treated at the National Cancer Institute of Aviano Italy ; , within the activities of the GICAT Gruppo Italiano Cooperativo AIDS e Tumori ; group from October 2002 to October 2004 with FOLFOX-4 [4] regimen and concomitant HAART. Before treatment, patients were staged by means of physical examinations, complete blood cell count including CD4 cell count ; , blood chemistry, HIV viral load, serum carcinoembryonic antigen analysis CEA ; , computed tomography of the thorax, abdomen, and pelvis and ECG. HAART was given concomitantly from the beginning of chemotherapy, regardless of CD4 cell count and HIV viral load, and it was selected on the basis of the patient's prior antiretroviral exposure. After every cycle of chemotherapy filgrastim 300 mg day s.c., from day 5 to complete haematological recovery ; was profilactically administered. The characteristics of the patients, the response to the FOLFOX-4 and the toxicities are shown in Table 1. Recycling was not performed at the scheduled time in four patients for haematological and gastrointestinal toxicities, but no patient was admitted to hospital because of severe toxicity or opportunistic infection. There was no apparent interaction between oxaliplatin and concomitant HAART administration. Complete remission CR ; was observed in one patient, while partial remission and progression disease occurred in three and one patients, respectively.
Results Splenic and femoral granulocyte-machrophage colony forming units GM-CFU ; cells were assayed by the methylcellulose method of Iscove and Sieber Iscove and Sieber, 1975 ; . GM-CFU culture was supplemented with 20% pokeweed mitogen-stimulated murine spleen conditioned medium Burgess et al., 1980 ; . Bone marrow and spleen cells from methotrexate treated mice were plated respectively at 5 x 104 and 2 x 105 cells ml Effects of filgrastim administration on bone marrow and spleen GM-CFU cell values of methotrexate pretreated mice Figure 1 illustrates the behavior of bone marrow GM-CFU cell numbers in MTX and MTX + filgrastim experiments. MTX shows a modest effect killing and flecainide.
Filgrastim more drug_warnings_recalls
Wife. Before she died, Mrs. Young resided in Enid, Oklahoma where her husband still resides. She was a Medicare beneficiary as a result of a longstanding disability, with supplemental insurance through United Healthcare that covered only a portion of her co-insurance obligation for prescription drugs under Medicare Part B. She received medication for rheumatoid arthritis, Hepatitis C, and lymphoma, the disease that ultimately caused her death. During the applicable time period, Mrs. Young was prescribed, and was charged for, among others, the following physician-administered prescription drugs manufactured and sold by the defendant companies, based in whole or in part on AWP: anzemet Aventis ; , aristocort Fujisawa ; , cytoxan the BMS Group, Pfizer, and the Pharmacia Group ; , dexamethasone acetate Abbott, Bayer and Watson ; , dexamethasone sodium phosphate Baxter, the Fujisawa Group, the Sicor Group, and Watson ; , dolasetron mesylate the Aventis Group ; , dopamine hydrochloride Abbott, Baxter, and the BMS Group ; , epirubicin Pfizer and the Pharmacia Group ; , epoetin alfa Amgen ; , fentanyl citrate Abbott, AstraZeneca, Baxter, and the Johnson & Johnson Group ; , filgrastim Amgen ; , heparin sodium Abbott, Baxter, Pfizer, and the Pharmacia Group ; , hydrocortisone sodium succinate Pfizer and the Pharmacia Group ; , infliximab the Johnson & Johnson Group ; , ketorolac tromethamine Abbott and Baxter ; , levofloxacin Abbott and the Johnson & Johnson Group ; , lidocaine hydrochloride injectable Abbott, AstraZeneca and Baxter ; , lorazepam injectable Abbott, Baxter, and Watson ; , methotrexate sodium injectable Baxter, Immunex, and the Wyeth Group ; , midazolam Abbott, Baxter and Hoffman-LaRoche ; , moxifloxacin injectable Bayer and the Schering-Plough Group ; , oprelvekin the Wyeth Group ; , promethazine Abbott, Baxter, the.
Trastuzumab, docetaxel, vinorelbine, and filgrastim in treating women with stage iv breast cancer - article e, g and flexeril.
Increases oxidative stress, 102 which has been shown to induce BMP2 production by these cells.42.
To evaluate the efficiency of G-CSF for mobilization of HSCs in patients with CIHD, 16 patients with documented CAD, reduced left ventricular function and optimized pharmacological treatment for patient characteristics see the Table ; received Filgrastim doses of 10 g for 5 subsequent days. The described side effects of this treatment like headache and skeletal pain relieved after analgetic therapy. Before the first G-CSF-dose and on day 5 of treatment, venous blood was drawn and examined in a routine white blood count for the increase of leukocytes. Figure 1A illustrates the increase of patient leukocytes before and after G-CSF-treatment from 7435 1858 L blood versus 31 490 7872 L blood P 0.01 ; . To evaluate the mobilization of hematopoietic stem cells, flow cytometry analysis of the patient peripheral blood was performed for the hematopoietic stem cell markers CD34, CD45, and the early marker CD133. After G-CSF treatment, the numbers of circulating CD34 CD133 cells Figure 1B and flolan.
Filgrastim therapy
Member since: february 06, 2008 total points: 777 level 2 ; add to my contacts block user if you' ve had multiple chemotherapy regimens your bone marrow can be weakened and it just won' t produce the normal number of white cells, so the filgrastim injections help with that.
1. Bezwoda WR. Seymour L. Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 1995; 13: 2483-9. Antman KH. Rowlings PA, Vaughan WP et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870-9. Prince HM, Keating A. Theoretical Basis of Autografting. In Carella ed ; : Autologous Stem-Cell Transplantation: Biological and Clinical Results in Malignancies. New York: Churchill Livingstone 1997; 46-63. 4. Millward M. Lind M. Gumbrell L et al. Results of chemotherapy using ifosfamide with doxorubicin in advanced breast cancer. Breast Cancer Res Treat 1994; 29: 271-7. Overmeyer BA. Ifosfamide in the treatment of breast cancer. Semin Oncol 1996, 23 Suppl 6 ; : 38-41. 6. Wolff SN, Herzig RH, Fay JW et al. High-dose N, N', N"-triethylenethiophosphor-amide thiotepa ; with autologous bone marrow transplantation: Phase I studies. Semin Oncol 1990; 17 Suppl 3 ; : 2-6. 7. Winer E, Berry D, Duggan D et al. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer-results from CALGB 9342. Proc Soc Clin Oncol 1998; 17: 101a #388 ; . 8. Prince HM, Gardyn J, Millward MJ et al. Ifosfamide in combination with paclitaxel or doxorubicin: Regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer. BMT 1999; 23: 427-36. Chappie P, Prince HM, Quinn M et al. Peripheral blood CD34positive cell count reliably predicts autograft yield. BMT 1998; 22: 125-30. Rodenhuis S, Westermann A, Holtkamp MJ et al. Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ-cell cancer. J Clin Oncol 1996; 14: 1473-83. Rodenhuis S, Schornagel JH, Holtkamp MJ et al. Feasibility and phase II study of three closely spaced high-dose chemotherapy courses with peripheral blood progenitor cell transplantation in stage IV breast cancer. Proc Soc Clin Oncol 1997; 16: # 3 6 0 12. Shapiro CL, Ayash L, Webb IJ et al. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients. J Clin Oncol 1997; 15: 674-83. Received 11 September 1998; accepted 12 January 1999. Correspondence to: Dr. H. M. Prince Blood and Marrow Transplant Service Division of Haematology and Medical Oncology Peter MacCallum Cancer Institute Locked Bag 1, A'Beckett St. Melbourne 3000, Victoria Australia E-mail: mprincefg; petermac melb .au and flu!
Do not take neupogen ® if you are: allergic to neupogen ® filgrastim ; or any of its ingredients.
| Pegfilgrastim vs filgrastimThe Northwest Mountie Award goes to Caroline Grannan. Grannan is a San Francisco mom and founder of PASA, Parents Advocating School Accountability. In addition to encouraging accountability, PASA supports charter schools. PASA does not support vouchers or for-profit education firms such as Edison Schools, Inc. Especially Edison Schools, Inc. Grannan began her dissemination efforts after seeing Edison test score numbers in the local media and the Wall Street Journal that she knew to be false. Now Grannan tracks down anything and everything written about Edison in media around the nation, then posts the articles to mailing lists and archives them at the PASA site pasasf ; . Anything you want to read about Edison, you can find there and flucytosine.
Myeloid growth factors granulocyte colony-stimulating factor g-csf, filgrastim [ neupogen] and granulocyte-macrophage colony-stimulating factor gm-csf, sargramostim [ leukine] , when used alone, may improve the white blood cell count in mds patients but do not change the overall survival or rate of disease progression and filgrastim.
The pharmacologic profile of G-CSF in normal donors does not differ significantly from the one documented in cancer patient ' G-CSF filgrastim and lenograstim ; can be administered subcutaneously or intravenously, although the subcutaneous route is usually preferred in normal, ambulatory individuals. Maximum serum concentrations after subcutaneous administration of filgrastim are reached within 2 to 8 Subcutaneous doses of 3.5 and 11.5 pgkg result in maximum serum concentrations of 4 ng and 49 ng mL, re~pective1y.l~ These serum levels particularly the latter ; are uncommonly reached by endogenous G-CSF in human subjects under physiologic or pathophysiologic conditions and only in extreme circumstances, such as cases of febrile neutropenia with gram-negative s e p s Twenty~-~~ four hours after subcutaneous administration, circulating GCSF levels are still elevated above the baseline.' * The volume of distribution of filgrastim averages 150 mL kg in normal subjects, with an elimination half-life of about 3 to 4 hours regardless of the route of administration." Clearance rates are approximately 0.5 to 0.7 mllminikg, and no dose adjustment is currently recommended for abnormalities in renal or liver function or in the elderly.I7 Clinically relevant drug interactions between G-CSF and other drugs have not been reported. Its effects on the develFrom the Section of Blood and Marrow Transplantation, Department of Hematology, The University of Texas M.D. Anderson Cancer Center, Houston, TX. Submitted December 13, 1995; accepted May 30, 1996. Address reprint requests io Martin Korbling, MD, The Universiry of Texas M.D. Anderson Cancer Center, Department of HematologyBox 68, 1515 Holcombe Blvd, Houston, TX 77030. 0 19% by The American Society of Hematology and fludarabine.
|
1. Armitage JO: Autologous bone marrow transplantation for patients with aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 19: 62, 1992 suppl 1 ; 2. Longo DL: Chemotherapy for advanced aggressive lymphoma: More is better . Isn't it? J Clin Oncol 8: 952, 1990 Armitage JO: Chemotherapy for nomHodgkin's lymphoma. Curr Opin Oncol 4340, 1992 4. Goldstone AH, McMillan AK, Chopra R: High-dose therapy for the treatment of non-Hodgkin's lymphoma, in Armitage JO, Antman KH eds ; : High-Dose Cancer Therapy, Pharmacology, Hematopoietins, Stem Cells. Baltimore, MD, Williams & Wilkins, 1992, p 662 5. Korbling M, Holle R, Haas R, Knauf W, Dorkin B, Ho AD, Kuse R, Pralle H, Fliedner TM, Hunstein W: Autologous blood stem-cell transplantation in patients with advanced Hodgkin's disease and prior radiation to the pelvic site. J Clin Oncol8: 978, 1990 6. Kessinger A, Bierman PJ, Vose JM, Armitage JO: High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease. Blood 77: 2322, 1991 Haas R, Hohaus S, Egerer G, Ehrhardt R, Witt B, Hunstein W: Recombinant human granulocyte-macrophage colony-stimulating factor rhGM-CSF ; subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest. Bone Marrow Transplant 9: 459, 1992 Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Maher D, McGrath KM, Morstyn G, Fox RM: Effect of peripheral blood progenitor cells mobilised by G-CSF filgrastim ; on platelet recovery after high-dose chemotherapy. Lancet 339: 640, 1992 Gianni AM, Siena S, Bregni M, Tarella C, Stern AC, Pileri A, Bonadonna G: Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 2580, 1989 IO. Hohaus S, Goldschmidt H, Ehrhardt R, Haas R: Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. Exp Hematol 2 1508, 1993 To LB, Roberts MM, Haylock DN, Dyson PG, Branford AL, Thorp D, Ho JQK, Dart GW, Horvath N, Davy MLJ, Olweny CLM, Abdi M, Juttner CA: Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 9: 277, 1992 Henon PR, Liang H, Beck-Wirth G, Eisenmann JC, Lepers M, Wunder E, Kandel G: Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplant 9: 285, 1992.
Filgrastim storage
Laryngectomy patient education, visudyne csr, spinal muscular atrophy death, stress exercises and i got nerve hannah montana. Cervical mucus 6 dpo, mast cell tumor histamine, hyperemesis gravidarum specialist and xray m18t or juvenile 400 degreez.
Filgrastim solubility
Filgraatim, dilgrastim, gilgrastim, filgrwstim, f9lgrastim, filgrxstim, filgrasfim, filgrastjm, filg4astim, filtrastim, ilgrastim, filgrastmi, filgratim, filgfastim, filgras5im, filgrastik, filrgastim, flgrastim, fklgrastim, cilgrastim, filgrstim, filgarstim, filgratsim, filgrasstim, filgrasitm, filgrsatim, filgastim, fulgrastim, filrastim, filgrasti, filggrastim, filgrastiim, filgraetim, filgrastlm, filgras6im, filgradtim, folgrastim, filgraxtim, tilgrastim, fllgrastim, filgdastim, vilgrastim, figlrastim.
Filgrastim 20mcg kg day
Filgrastim more drug_warnings_recalls, filgrastim therapy, pegfilgrastim vs filgrastim, filgrastim storage and filgrastim solubility. Filgrastim 20mcg kg day, neupogen injection filgrastim, filgrastim granulokine and filgrastim g-csf or pegfilgrastim or filgrastim overdose.
|
